Paradigm Biocapital Advisors has significantly reduced its stake in Erasca (NASDAQ: ERAS), selling 3,766,393 shares valued at approximately $44.52 million in Q1 2026. This divestment comes after Erasca’s stock surged over 700% in the past year, driven by promising early trial results for its oncology therapies targeting RAS mutations. Following the sale, Paradigm’s holdings in Erasca now represent 3.44% of its assets under management (AUM).

This transaction highlights the volatility inherent in biotech investments, particularly following substantial price increases. Erasca’s stock experienced a sharp decline after a patient death during a clinical trial and a competitor’s patent infringement claims, underscoring the risks associated with early-stage biotech stocks. The firm’s decision to lock in gains before potential downturns illustrates a prudent approach in a sector characterized by rapid fluctuations.

For market professionals, this case serves as a reminder of the importance of profit-taking strategies, particularly in speculative sectors where clinical data can dramatically influence stock performance.

Source: fool.com